NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

With that being the case, the question may be, does adding either Keytruda or more of the Poly-ICLC during treatment improve the outcome, or is the key what's incorporated into the DCVax-L when it's made.

The big question that will be answered over time is whether the greatly increased T-cell production with your own T-cells is more effective than CAR-T treatments which may cure one cancer while creating others over time. Perhaps both are needed, but perhaps the risk from CAR-T can be reduced if lower doses are as effective when used with DCVax-L.

I don't know if improvements have been made in CAR-T that sustains it's effectiveness. When I discussed it with my Dr. at City of Hope who's done some of the pioneering work in its development, he indicated that it's only effective for a matter of a few days, if it doesn't knock out the disease in that time it will return in time. It was shortly after my stem cell transplantation that I discussed it, so nearly 10 years ago, I really don't know how much further it advanced since then.

While it's clear that if CAR-T is the only choice to cure a specific cancer it should be used even if it means routinely monitoring the patient the rest of their life for other cancers it may cause. On the other hand, if DCVax-L and Direct prove to be of equal or greater benefit, in time CAR-T might not be used at all.

Gary